Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

After Balancer and Yearn suffered major exploits, new entrants like Axis are betting that transparency and off-chain ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

Oncolytics Biotech Inc. (NASDAQ: ONCY) has secured FDA alignment on its pivotal Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning the company to launch the ...

And other pharma news rounded up from around the Pharmalot campus, as told to you by the Pharmalittle newsletter ...

For decades, software developers have been slipping jokes into their work. One of the most enduring, clever, and geekily satisfying inside jokes has been hiding in plain sight: the recursive acronym.

November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies ...

As language models (LMs) improve at tasks like image generation, trivia questions, and simple math, you might think that ...

As language models (LMs) improve at tasks like image generation, trivia questions, and simple math, you might think that ...

Citius Oncology entered into an exclusive distribution agreement with Er-Kim to expand international access to Lymphir (denileukin diftitox-cxdl) in Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia ...

PsiThera, formerly Psivant Therapeutics, raised just over $47 million for oral drugs targeting “diseases long-constrained by ...

Arrowhead Pharmaceuticals, Inc. today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the company's investigational RNA interference (RNAi) therapeutic being ...